Excalipoint Therapeutics Launches with $68.7 Million to Develop Next-Gen T-Cell Engager Therapies
“Excalipoint is developing a proprietary pipeline and three powerful technology platforms to position our company as a true innovation powerhouse and developer of T-cell engagers,” said Lei Fang, Ph.D., Co-Founder, Chairman and Chief Executive Officer, Excalipoint Therapeutics. “By combining science and capital with China’s clinical development efficiency and access to large patient populations, we can rapidly generate clinical data while advancing a pipeline of differentiated therapies. Our progress reflects the strength and maturity of China’s biotech ecosystem, which has become an essential part of the global innovation value chain. The strong support from top-tier investors validates both our science and this new approach to building a globally competitive biotechnology company.”
Share:
More News
“The designation reinforces the significant unmet need for effective treatment options for patients with advanced breast cancer,” said Charles Baum, M.D., Ph.D., Chief Executive Officer of Terremoto Biosciences. “We are committed to advancing highly selective therapies designed to expand treatment options for patients with difficult to treat cancers.”
“Up to five U.S. clinical sites are planned for THIO-101 Parts C and D this year, and we expect to activate a second U.S. site in the coming weeks,” said Vlad Vitoc, M.D., Founder and Chief Executive Officer of MAIA. “To date, data has shown overall survival (OS) beyond two
Dr. Jason Zhu, Executive Director and Chief Executive Officer of Henlius, said: “The positive CHMP opinion for the sqNSCLC indication marks another important milestone in serplulimab’s regulatory journey in Europe and brings the product one step closer to achieving comprehensive coverage of first-line lung cancer treatment indications in the EU.